Dexmedetomidine (DEX)
Dexmedetomidine (DEX) is a pharmaceutical drug with 5 clinical trials. Currently 3 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 1 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
1
Mid Stage
2
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
100.0%
1 of 1 finished
0.0%
0 ended early
3
trials recruiting
5
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Dexmedetomidine and Propofol for Sedation in Cataract Surgery.
The Effect of Dormicum-Ketamine Versus Dexmedetomidine on Emergence Delirium During Deep Sedation in Paediatric Burn Patients
The Effect of Dexmedetomidine Infusion Alone Versus the Combination of Dexmedetomidine and Melatonin on Reduction of Post-operative Delirium (POD) After Open Brain Surgeries
Early Dexmedetomidine and Sympathetic Regulation in Sepsis
Cardioprotective Effect of Dexmedetomidine in Patients With ST-segment Elevation Myocardial Infarction
Clinical Trials (5)
Dexmedetomidine and Propofol for Sedation in Cataract Surgery.
The Effect of Dormicum-Ketamine Versus Dexmedetomidine on Emergence Delirium During Deep Sedation in Paediatric Burn Patients
The Effect of Dexmedetomidine Infusion Alone Versus the Combination of Dexmedetomidine and Melatonin on Reduction of Post-operative Delirium (POD) After Open Brain Surgeries
Early Dexmedetomidine and Sympathetic Regulation in Sepsis
Cardioprotective Effect of Dexmedetomidine in Patients With ST-segment Elevation Myocardial Infarction
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5